How Immunotherapy Works to Combat Cancer

Cancer develops when abnormal cells grow and divide in ways the body does not fully control. Normally, the immune system helps recognize and remove damaged or dangerous cells. Immunotherapy is a category of treatments that supports or redirects this natural defense so it can better find and destroy cancer cells while aiming to spare most healthy tissue.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

How immunotherapy treatments work with the immune system

The immune system relies on a complex network of cells and signals to distinguish normal cells from threats such as viruses, bacteria, or cancer cells. T cells, a type of white blood cell, play a central role in recognizing and attacking abnormal cells. Cancer can escape this surveillance by hiding its identity, sending “don’t attack” signals, or creating a protective environment around the tumor.

Many immunotherapy treatments work with the immune system by adjusting these signals. Checkpoint inhibitors, for example, block proteins such as PD‑1, PD‑L1, or CTLA‑4 that act like brakes on T cells. When these brakes are blocked, T cells may become more active against cancer. Other approaches mark cancer cells so they are easier for immune cells to detect, or they supply immune‑stimulating signals that strengthen existing responses.

Because these therapies influence the immune system rather than directly attacking the tumor with radiation or traditional chemotherapy drugs, their effects can be different. Some people may experience delayed but long‑lasting responses, and some tumors that were resistant to older treatments may shrink or become stable.

Different types of immunotherapy

There are several different types of immunotherapy, each using a distinct strategy to involve the immune system in cancer treatment. Immune checkpoint inhibitors are among the most widely used. These medicines are often given through an intravenous infusion and have changed care for cancers such as melanoma, lung cancer, kidney cancer, bladder cancer, and others.

CAR T‑cell therapy is another form of immunotherapy. In this approach, some of a patient’s T cells are removed, genetically modified in a laboratory to better target cancer, and then returned to the bloodstream. CAR T‑cell therapies are currently used mainly for certain leukemias and lymphomas.

Cancer vaccines are designed to help the immune system recognize cancer‑specific markers. Some target virus‑related cancers, while others are individualized based on proteins found in a person’s tumor. Monoclonal antibodies may act by binding to cancer cells, blocking growth signals, or delivering toxic substances directly to tumors.

Other types include cytokine therapies, which use immune‑signaling proteins such as interleukins or interferons, and oncolytic virus therapies, which use modified viruses that preferentially infect and damage cancer cells while alerting the immune system to their presence.

What can patients expect from treatment?

Before starting immunotherapy, patients typically undergo a detailed evaluation. This may involve reviewing medical history, imaging studies, blood tests, and sometimes tissue testing for specific biomarkers such as PD‑L1 levels, certain gene changes, or markers of high mutation rates. These results can help clinicians determine whether an immunotherapy approach is suitable.

Immunotherapy can be delivered in different ways. Many checkpoint inhibitors are given as infusions at a hospital or outpatient clinic every few weeks. Some drugs are taken as tablets or capsules. CAR T‑cell therapy usually requires a more complex process, often including a hospital stay. The overall plan depends on the type of cancer, stage of disease, previous treatments, and general health.

During treatment, patients can expect regular monitoring for both effectiveness and side effects. Imaging scans and lab tests are used to track changes in the tumor and in organ function. It is not unusual for scans to show mixed results, or even temporary tumor swelling, as immune cells move into the cancer. This makes it important for experienced clinicians to interpret results and decide whether to continue, change, or stop therapy.

Benefits and potential side effects of immunotherapy

For some people, immunotherapy brings meaningful benefits. Tumors may shrink or stop growing for extended periods, even after treatment ends. In certain cancers, a portion of patients experience long‑term disease control, sometimes referred to as durable responses. Because these treatments target the immune system rather than all rapidly dividing cells, some patients report different side effect patterns compared with traditional chemotherapy.

At the same time, immunotherapy can cause significant side effects. When the immune system becomes highly activated, it may mistakenly attack healthy organs. These immune‑related adverse events can affect the skin, intestines, liver, lungs, hormone‑producing glands, joints, or other tissues. Symptoms might include rash, diarrhea, shortness of breath, fatigue, headaches, or changes in weight and mood.

Many side effects are manageable if recognized early. Clinicians may use corticosteroids or other medicines to calm an overactive immune response, adjust the treatment schedule, or stop therapy if needed. People receiving immunotherapy are usually advised to report new or worsening symptoms promptly so the care team can respond quickly and reduce the risk of serious complications.

How immunotherapy can fight multiple types of cancer

Immunotherapy has been approved for a growing list of cancers. These include melanoma, non‑small cell lung cancer, small cell lung cancer, kidney and bladder cancers, certain head and neck cancers, Hodgkin lymphoma, some non‑Hodgkin lymphomas, specific types of leukemia, and some colorectal and other solid tumors with particular genetic features.

Eligibility for immunotherapy depends on the type and stage of cancer, overall health, and sometimes the presence of specific biomarkers. For example, tumors that show a pattern called high microsatellite instability or defective mismatch repair may respond well to certain checkpoint inhibitors, regardless of where in the body the cancer began. Other cancers may require a combination of immunotherapy with chemotherapy, targeted therapy, radiation, or surgery.

Research continues to explore why some tumors respond strongly to immunotherapy while others do not, and how to overcome resistance. Clinical trials in the United States and worldwide are testing new drug combinations, dosing strategies, and personalized approaches that match treatments to the features of each person’s cancer and immune system.

In summary, immunotherapy represents an important advance in cancer care by engaging the body’s own defenses against tumor cells. While it does not replace all other treatments and does not work for everyone, it offers new possibilities for many people living with cancer. Careful evaluation, close monitoring, and informed discussions between patients and healthcare professionals are essential to determine whether a particular immunotherapy approach fits an individual situation.